Introduction {#s0005}
============

Human-papilloma virus positive (HPV+) oropharyngeal cancer (OPC) is epidemic in the United States, with an estimated 20,000 new cases annually, and rising incidence projected in the coming decades [@b0005]. HPV+ cancers are sensitive to radiotherapy but despite excellent survival outcomes and the introduction of intensity modulated radiotherapy, current regimens continue to be associated with toxicity to adjacent normal tissue [@b0010], [@b0015], [@b0020], [@b0025], [@b0030], [@b0035], [@b0040]. This leaves comparatively young survivors with potentially quality-of-life altering, permanent radiation sequelae that can persist for decades of survivorship, and limit future compensatory functionality in the face of new challenges [@b0045], [@b0050], [@b0055], [@b0060]. To address this issue, it is necessary to find the optimal therapeutic window of HPV+ OPC, where dose to organs at risk (OARs) can be reduced while tumoricidal doses to active tumor volumes can be achieved. However, safely achieving this target by anatomically adapting the dose to follow serially shrinking tumor volumes during the 6--7 week radiation therapy course is currently impossible using CT without repeated use of exogenous contrast. In addition, existing functional imaging biomarkers, such as radiolabeled positron emission tomography (PET) tracers cannot be safely repeated iteratively during treatment. Therefore, the ability to image tumors during therapy to adapt radiation fields for responding tumors, reducing OAR dose and subsequent toxicity, is currently an unmet need.

Adaptive radiotherapy strategies have been previously implemented at our facility [@b0065], [@b0070]. Schwartz et al. performed adaptive replanning mid-therapy for head and neck cancer patients, using daily computed tomography (CT)-on-rails image-guidance. The lack of contrast delivery for the CT-on-rails impeded the accurate visualization of tumor changes during treatment, and thus did not allow for reduction of clinical target volumes as tumor shrank, but instead accounted for weight-loss and normal tissue deformation [@b0065], [@b0070]. Magnetic resonance imaging (MRI) provides superior tumor/soft tissue contrast [@b0075]. In a recent study by our group [@b0080], 31 patients with locally advanced HPV+ OPC were examined for mid-treatment response as assessed by MRI. The study showed that approximately 50% of patients had complete resolution of clinical and radiographically primary disease at mid-therapy. Using serial MRI-guided dose adaptation in this cohort of patients would allow selective, patient-specific precise dose-reduction, such that patients with brisk radiation response would have commensurate dose reduction, while comparatively radiation resistant tumor subvolumes would be ensured a tumoricidal dose. Using serial in-treatment MRI without exogenous/IV contrast, we can potentially track tumor shrinkage during treatment, conceivably de-escalating OARs doses to reduce side effects without sacrificing locoregional control and survival.

In this dosimetric study, we propose a novel MRI-guided IMRT dose-adaption strategy for HPV+ OPC, whereby dose to gross disease is reduced on an "as needed" basis, such that responders could achieve substantive dose reduction to adjacent normal tissue at levels not observed with standard radiotherapy, while non-responsive disease would not be *a priori* de-escalated. This represents a truly "personalized" therapy, as, rather than assigning dose *a priori*, the cumulative dose received by each patient would be predicated on imaging response. To this end, we aim to determine the feasibility and dosimetric benefits of this MRI-based dose-adaption strategy for HPV+ OPC patients using serial in-treatment MRIs acquired in radiation treatment positioning and immobilization setup.

Materials and methods {#s0010}
=====================

Patients {#s0015}
--------

Patients in the current study were prospectively enrolled under an Institutional Review Board (IRB)-approved imaging protocol (PA14-0582) after signing a study-specific informed consent form. Patients were scanned between July 2015 and June 2016. Inclusion criteria were age older than 18 years; histologically proven P16+ oropharyngeal squamous cell carcinoma; eligibility for definitive IMRT; intact primary tumor; Stage III, IVa, or IVb disease as defined by American Joint Committee on Cancer (AJCC) 7th edition cancer staging criteria; ECOG performance status of 0--2; no administration of induction chemotherapy before radiotherapy; and no contraindications to MR imaging.

MRI protocol {#s0020}
------------

Serial MRI simulation images were acquired at baseline (within one week prior to first radiation fraction), and every two weeks during the IMRT course (i.e. at weeks 2, 4, and 6). Patients were dispositioned to receive a custom-fitted oral stent and an immobilization mask same to that used for radiotherapy treatment planning prior to receiving their study MRIs. The stent was made by the dental oncology team to hold the tongue and the remainder of the oral cavity in place. The thermoplastic mesh mask, for the head and neck region, was made during the simulation phase to immobilize the head, neck, and shoulders of the patient in a reproducible way. We previously detailed the positioning and immobilization setup for our MRI-simulation process in a separate publication [@b0085].

Patients' images were acquired using a 3.0 T MR scanner (Ingenia, Philips Healthcare, Best, The Netherlands) with two SENSE Flex-M coils laterally and SENSE spine coil posteriorly. MRI sequences included axial T2 weighted image (repetition time/echo time = 8755/100 ms, echo train length = 15, field of view = 25.6 cm, spatial resolution = 0.5 × 0.5 × 2.5 mm^3^, number of signal averages = 2, pixel bandwidth = 184 Hz, number of slices = 90). Geometrical scan parameters were prescribed for a standardized spatial region encompassing the vertex cranially to the cricoid cartilage caudally for all scans.

CT simulation {#s0025}
-------------

Standard simulation CTs were acquired for each patient at baseline prior to treatment, followed by serial simulation CT imaging for adaptive replanning at the same time points of MR-simulation (i.e. at weeks 2, 4, and 6) using identical positioning and immobilization setup (see schema of protocol, [Fig. 1](#f0005){ref-type="fig"}).Fig. 1Schema of *in silico* adaptive planning protocol.

Target volumes and dose specification {#s0030}
-------------------------------------

Target volumes were delineated by the study PI (CDF) and were peer reviewed by MD Anderson's Radiation Oncology Head-and-Neck Planning and Development Clinic. The process of peer-review of segmented contours was explained in details in a prior report by our group [@b0090]. In brief, the process entails comprehensive review of a patient's history, pathology, diagnostic imaging, and discussion of the planned treatment. All patients undergo physical examination (PE) including video-camera nasopharyngolaryngoscopy and bimanual palpation performed by a team of head-and-neck radiation oncology sub-specialists. The proposed segmentations were reviewed slice-by-slice for gross tumor volume (GTV), clinical target volume (CTV) and OAR segmentation, as well as dose-volume specifications. By this manner, intra- and inter-observer variability in segmentation are minimized because of the utilization of multi-observers agreement contours rather than single-observer contours.

The initial gross tumor volume (e.g. GTV_p~initial~ for primary disease and GTV_n~initial~ for nodal disease) was manually segmented using T2-weighted MR images at baseline then propagated to the co-registered simulation CT acquired at the same day. The initial clinical target volume (CTV~initial~) was defined as the GTV~initial~ plus 5 mm expansion, trimmed from uninvolved bone, muscle, skin or mucosal surfaces; to incorporate high-risk subclinical disease.

For each patient, two IMRT plans were created: a standard and an adaptive treatment plan. The prescription dose for the standard plans was 2.12 Gy/fx for 33 fractions to the PTV~initial~ (CTV~initial~ +3mm). For adaptive plans, a new GTV~adaptive~ was segmented on serial MRIs using T2-weighted MR images at time points showing a detectable shrinkage of the GTV~initial~. Subsequently, a new CTV~adaptive~ was generated to cover the GTV~adaptive~ propagated from MRI to the corresponding same day CT with additional 5 mm margin. Detectable shrinkage was defined as any GTV~initial~ reduction of more than 2 mm in the reference plane (largest cross sectional distance axially on the pretherapy imaging).

The prescription dose to PTV~adaptive~ (CTV~adaptive~ +3mm) was 2.12 Gy/fx to allow delivery of maximum dose to the residual disease, resulting in a cumulative dose, should disease persist through therapy, of up to 70 Gy. Prescription dose for any previously involved volumes was 1.52 Gy/fx to ensure a minimum "floor" dose of 50.16 Gy to any region ever deemed to have been directly involved with tumor. All uninvolved upper-neck elective nodal volumes outside the CTV~initial~/CTV~adaptive~ were encompassed in the CTV~elective~, and prescribed 1.52 Gy/fx for a total prescription of 50.16 Gy/33 fractions. [Fig. 2](#f0010){ref-type="fig"} illustrates the workflow for adaptive vs. standard plans.Fig. 2Adaptive dose reduction workflow shown on the left; as GTV (green) shrinks, so does the high dose (CTV 2.12 Gy/day region) which become included in the low dose target (CTV 1.52 Gy/day region). Standard radiotherapy doses are shown on the right. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

OAR segmentation {#s0035}
----------------

Organs at risk (OARs) were auto-segmented on simulation CTs at baseline and at weeks 2, 4, and 6 using a previously validated atlas-based auto-segmentation software program ADMIRE v1.13 (Elekta AB, Stockholm, Sweden). This was followed by review and correction of the contours when needed by an experienced radiation oncologist (ASRM). The following OARs were included: spinal cord; brain stem; bilateral parotid and submandibular glands; thyroid gland; larynx; oral cavity; brachial plexus; superior, middle, and inferior pharyngeal constrictors; medial and lateral pterygoid muscles; masseter; sternocleidomastoid; intrinsic and extrinsic tongue muscles; hard palate; and soft palate.

Radiation planning {#s0040}
------------------

All plans were optimized to full dose (70 Gy or 50.16 Gy if no residual disease was present) to keep the total dose to each OAR below the tolerance limit for every adaptive plan while maintaining at least 99% coverage to the PTV with a hot spot less than 110% to ensure that no normal tissue limit would be reached for a specific organ before the end of treatment. Once the plan was finalized, the number of fractions was adjusted to the number that would be delivered for the next adaptive phase. Dose accumulation was performed at the end of each adaptive phase to ensure target volumes met prescription dose and OARs met dose constraints.

Planning was performed with Pinnacle3 v.9.10 (Philips Medical Systems, Fitchburg, WI). All patients were planned with volumetric modulated arc therapy. For bilateral neck irradiation, two 360 degree arcs were utilized, while for cases of unilateral neck irradiation, two half arcs were used. The duration of the MRI-simulation was one hour and the duration of segmentation and replanning was four hours per patient.

Statistical analysis {#s0045}
--------------------

Three dimensional volumetric changes of GTV_p and GTV_n were recorded at all time points. Dosimetric parameters of target volumes and OARs were recorded for standard vs. adaptive plans for each patient. Subsequently, normal tissue complication probability (NTCP) for toxicity endpoints was calculated using literature-derived multivariate logistic regression models [@b0095], [@b0100], [@b0105], [@b0110]. The toxicity endpoints examined were: 1) persistence of feeding tube 6 months after treatment [@b0095], 2) grade ≥2 dysphagia 6 months after treatment [@b0100], 3) hypothyroidism 12 months after treatment [@b0105], and 4) xerostomia 6 months after treatment [@b0110]. The rationale for NTCP model selection was detailed in a previous publication by our group [@b0115]. All statistical analyses were performed using statistical software (JMP Pro version 11, SAS Institute, Cary, NC).

Results {#s0050}
=======

Five patients were included in this pilot study; 3 men and 2 women. Median age was 58 years (range 45--69). Three tumors originated at the tonsillar fossa and two at the base of tongue. Patient demographic, disease, and treatment characteristics are summarized in [Table 1](#t0005){ref-type="table"}.Table 1Patient demographic, disease, and treatment characteristics.PatientOriginGenderAge (years)Smoking historyT stageN stageAJCC stageConcurrent chemotherapy1TonsilFemale45NeverT2N2cIVAWeekly Cisplatin2Base of TongueMale60NeverT2N1IIINo chemotherapy3TonsilFemale69FormerT2N2bIVAWeekly Cetuximab4TonsilMale51NeverT2N2cIVAWeekly Cisplatin5Base of TongueMale58NeverT2N2bIVAWeekly Cetuximab

The average decrease in GTV_p volume at weeks 2, 4, and 6 was 44%, 90%, and 100%, respectively. The GTV_n volume shrinkage, however, had a relatively slower pace with average decrease in GTV_n volume at weeks 2, 4, and 6 of 25%, 60%, and 80%, respectively. These significant shrinkage qualified all patients for adaptive plans at weeks 2, 4, and 6. The course of target volume response is presented graphically in [Fig. 3](#f0015){ref-type="fig"} for all patients included in the analysis.Fig. 3Details of volumetric response of target volumes for all patients at each time point, over the course of therapy. Patient 2 had an excisional biopsy prior to definitive IMRT and, therefore, had no GTVn at radiation start.

Results demonstrated that the vast majority of OARs showed a decrease in dosimetric parameters when adaptive plans were used compared with standard plans, particularly for swallowing related structures, as illustrated in [Table 2](#t0010){ref-type="table"}. Regarding target volumes, the average dose to 95% of PTV~initial~ volume was 70.7 Gy (SD, 0.3) for standard plans versus 58.5 Gy (SD, 2.0) for adaptive plans. Details of dose parameters for target volumes are presented in [Supplementary Table 1](#s0080){ref-type="sec"}.Table 2Dosimetric criteria of organs at risk using standard vs adaptive plans.Organ at risk (OAR)Mean dose Standard IMRT in GyStandard Deviation Standard IMRT GyMean dose Adaptive IMRT in GyStandard Deviation Adaptive IMRT GySupraglottic larynx52.710.745.810.4Glottic larynx33.821.731.018.9Superior pharyngeal constrictor62.86.758.15.0Middle pharyngeal constrictor51.616.448.412.5Inferior pharyngeal constrictor34.723.332.018.6Cricopharyngeus muscle30.019.027.517.5Mylo/geniohyoid muscle37.810.533.411.2Intrinsic tongue muscles44.714.540.112.9Genioglossus muscle51.813.547.411.0Oral cavity42.111.338.010.8Soft palate55.010.749.210.6Ipsilateral ant. Digastric muscle44.46.940.67.1Contralateral ant. Digastric muscle29.910.226.012.7Ipsilateral parotid gland30.211.326.98.3Contralateral parotid gland17.48.616.58.4Ipsilateral submandibular gland69.73.665.06.0Contralateral submandibular gland40.920.339.919.6Esophagus19.212.316.89.9Brain Stem10.81.98.32.7Spinal cord21.86.521.28.0Thyroid gland36.123.232.820.7

Using NTCP models, the average reduction of the probability of developing dysphagia ≥ grade 2 and feeding tube persistence at 6-month post-treatment using adaptive strategy was 11% (37% vs 26%, odds ratio (OR) = 0.6, 95% CI 0.2--1.5) and 4% (10% vs 6%, OR = 0.5, 95% CI 0.1--3), respectively as depicted in [Fig. 4](#f0020){ref-type="fig"}.Fig. 4Boxplots depicting the comparison of normal tissue complication probability (NTCP) between standard and adaptive methods.

The probability of developing hypothyroidism at 1-year post-treatment was also reduced by average 5% (41% vs 36%, OR = 0.8, 95% CI 0.3--2) while the probability of xerostomia at 6-month was only reduced by average 1% for adaptive plans compared with standard IMRT (35% vs 34%, OR = 0.95, 95% CI 0.4--2.5).

Discussion {#s0055}
==========

In this study, we report the feasibility of an MRI-guided IMRT dose-adaption workflow for HPV+ OPC. To our knowledge, this is the first study reporting on the dosimetric advantage of MRI-based adaptive radiation de-intensification in head and neck cancers. The proposed approach was associated with an average reduction in the dose to the PTV of 12 Gy. Adaptive replanning was associated with reduction of dose to the OARs, in particular to the swallowing musculature, which translated into a reduction of the odds of dysphagia ≥ grade 2, feeding tube persistence at 6-months, and hypothyroidism at 1-year post-treatment.

HPV+ OPC has been shown to be a favorable subtype of head and neck cancer with improved prognosis compared to non-HPV+ OPC [@b0120], [@b0125]. The distinctive epidemiologic, clinical and molecular characteristics [@b0130] of HPV+ OPC are now reflected in the new cancer staging proposed in the American Joint Committee on Cancer 8th edition [@b0135]. Given the excellent outcomes of HPV+ OPC, it is increasingly considered that many patients with HPV+ OPC may be over-treated with current standard chemoradiation. It is, in fact, recognized that current standard treatment is associated with high rates of toxicities that were shown to adversely impact patients' health-related quality of life [@b0140]. Given the high probability of long-term survival and typical young age of patients with HPV+ OPC, treatment de-intensification aiming at reducing long-term toxicities and improving survivorship has become a central concern in the management of these patients [@b0145]. To this end, multiple clinical trials are currently on-going to assess various treatment de-escalation strategies in this group [@b0150], [@b0155].

The overall goal of all treatment de-intensification strategies is to maintain excellent cancer outcomes while reducing morbidity. Current evaluated strategies include the use of targeted therapies versus systemic chemotherapy [@b0150], reduced radiation dose based on response to induction chemotherapy response [@b0160], [@b0165], [@b0170], or modulation of radiation dose in the context of chemoradiation [@b0175], [@b0180]. Proton therapy may be also an alternative way to reduce normal tissue toxicity and is currently investigated in a randomized trial (NCT01893307) comparing IMPT versus standard IMRT. A recent study by Blanchard et al. demonstrated the validity of a set of NTCP models for head and neck cancer patients treated with proton therapy. However, improvement in model performance remains to be required for better selection of patients for proton therapy [@b0185]. Furthermore, minimally invasive surgery such as trans-oral robotic surgery (TORS) has been also introduced as an alternative approach to avoid radiation toxicity with equivalent oncologic outcomes [@b0190]. An ongoing randomized clinical trial (NCT02984410) is currently assessing the patient-reported swallowing function over the first year after randomization to either IMRT or TORS in OPC patients.

It is fairly well established that radiation dose is closely related to radiation-induced long-term toxicities, notably to rates and severity of dysphagia as well as rates of stricture formation, feeding tube dependence and aspiration [@b0195], [@b0200], [@b0205]. In a recent systematic review by Duprez et al., mean dose to pharyngeal constrictors was the strongest predictor of late swallowing dysfunction, with clinical reduction of swallowing dysfunction observed with dose of 52--55 Gy vs. 61--64 Gy, suggesting that even mean OAR dose reduction of less than 10 Gy could translate into clinically impactful toxicity reduction [@b0210]. In this context, de-escalation strategies aiming at reducing radiation dose are particularly appealing. Chera et al. [@b0175] recently investigated rates of complete response of a de-intensified chemoradiation strategy in favorable risk HPV+ OPC. Treatment de-escalation consisted of delivery of 60 Gy to the gross disease and reduced cisplatin dose (30 mg/m^2^ weekly). The reported clinical complete response rates reached 98% and 60% at the primary and regional sites respectively, suggesting that dose de-escalation may be suitable in selected patients. However, the optimal strategy for patients' selection, notably the potential role of adaptive de-escalation based on individual response, remains to be investigated.

The principle of adaptive radiotherapy planning relies on monitoring temporal and spatial anatomical changes over the course of radiotherapy, and modulating radiation dose based on observed changes. These changes can include changes in target volumes, OAR volume or shape, weight loss, alteration in muscle mass, or edema [@b0065], [@b0215], [@b0220]. Several previous studies have assessed the role of per-treatment imaging response during the course of radiotherapy for head and neck cancer, including CT [@b0065], [@b0070], [@b0225], [@b0230], PET-CT [@b0235], anatomic MRI and functional MRI (diffusion weighted or dynamic contrast enhanced) [@b0240], with tumor changes observed in the majority of patients, as early as by fraction 11 [@b0245]. Using CT-on-rails image guidance in patients undergoing head and neck radiotherapy, Schwartz et al. at reported that all patients benefited from at least one re-plan and 36% required a second re-plan to account for weight loss, CTV and normal tissue changes [@b0065], [@b0070]. More recently, Lee et al. [@b0180] reported outcomes of an adaptive approach consisting of 10 Gy dose de-escalation to involved lymph nodes based on early treatment hypoxia assessment using 18F-fluoromisonidazole-PET. Among 33 patients, 30% received reduced radiation dose; 2-year locoregional control rate was as high as 100%. This study suggests that functional imaging may play an important role in guiding adaptive radiation strategies. The increasing use of MRI for head and neck radiotherapy planning has the advantage of improved soft-tissue visualization [@b0075], which allows to more confidently assess anatomical tumor changes during treatment. In addition, MRI also offers the possibility of frequent per-treatment functional assessment, without the addition of ionizing radiation. The recent introduction of the MR-Linac technology holds the promise to facilitate such adaptive IMRT workflows by mean of daily on-line MRI during radiation treatment [@b0250].

This *in silico* study is limited by its small sample size. However, the aim of this study was to establish the feasibility and the dosimetric advantage of this proposed MRI-guided IMRT dose-adaption workflow for HPV+ OPC, in preparation for future clinical application. In addition, this study used only anatomical MR-sequences for treatment adaption. However, although the role of functional MRI certainly seems promising for assessment and prediction of tumor response [@b0240], observed functional changes require further investigation to establish clear thresholds to be used clinically for treatment adaptation. Finally, the safety, in terms of cancer control outcomes, as well as the toxicity advantages of this workflow will be validated in an upcoming clinical trial by our institution. The results of this study guided the sample size calculation of this upcoming phase II clinical trial designed to validate the superiority of MRI-guided radiotherapy dose adaptation for improving the toxicity profile of HPV+ oropharyngeal cancers without compromising the outcomes.

Conclusion {#s0060}
==========

This *in silico* results showed the suggested MRI-guided adaptive approach is technically feasible, safe (with no normal tissue exceeding modeled dose constraints), and advantageous in reducing dose to OARs, especially swallowing musculature, thus reducing the NTCP of dysphagia ≥ grade 2, feeding tube persistence at 6-month post-treatment, and hypothyroidism at 1-year post-treatment.
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